Neutral
●
GlobeNewsWire
●
5 months ago
NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approv...